Celtic Finance Institute

News Details

April 28, 2025

Boeing, Jack in the Box, Eli Lilly: Trending Tickers

Brad Smith and Madison Mills take a closer look at some of today's trending tickers and top calls from Wall Street analysts on Morning Brief.

Boeing ( BA ) is in focus after Bernstein analysts upgraded the stock to Outperform from Market Perform.

Jack in the Box ( JACK ) also saw a rating upgrade from Stifel analysts, who upgraded the company's stock to Buy from Hold.

Eli Lilly ( LLY ), on the other hand, saw a double downgrade from HSBC analysts.

To watch more expert insights and analysis on the latest market action, check out more Morning Brief here .

00:00 Speaker A

We're taking a closer look at some trending tickers this morning and we're doing it in 30 seconds each. We're looking at Boeing, Jack in the Box, and Eli Lilly. First up, Boeing raised to outperform from market perform at Bernstein. The firm says the plane maker is quote "making the progress it needed for the growth trajectory." The analysts maintain that they cannot assume all risks are gone, but that the company should be on a better path now after increased scrutiny. Bernstein set its price target on the stock to $218, 23% upside from the stock's last close.

00:40 Speaker B

Plus, Jack in the Box upgraded to buy from hold at Stifel. The firm touting the fast food chain's new CEO, Lance Tucker, saying Tucker quote "has created a viable plan to strengthen the balance sheet." The analyst says Jack in the Box's decision to close a couple hundred underperforming units puts it in a stronger competitive position. The firm set a $32 price target, 31% upside from stock's last close.

01:08 Speaker A

And finally, Eli Lilly, getting a double-downgrade from HSBC to reduce, the equivalent of a sell rating, from buy. The firm says Lilly's price target or the risk reward rather, is quote "not attractive" and the analysts think that the market may be overstating or overestimating perhaps, Lilly's market share and that uncertainties in the economy may pressure demand for GLP1s. The firm also has concerns around Lilly's new weight loss drug. HSBC reducing its price target to $700, that represents 21% downside from the stock's last close.

01:49 Speaker B

Quite a call there. All right. You can scan the QR code below to track the best and worst performing stocks with Yahoo Finance's trending tickers page.

Related Videos

OK